Sp106

PANEL DISCUSSION

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed. This session will examine all treatment options, review the importance of treat to target in EoE and examine if the endpoint of the disease, fibrosis can be reversed now or in the future. LIVE STREAM SESSION

Presenters

Speaker Image for Glenn Furuta
Children
Speaker Image for Nirmala Gonsalves
Northwestern University - The Feinberg School of Medicine
Speaker Image for Amanda Muir
The Children's Hospital of Philadelphia
Speaker Image for Evan Dellon
University of North Carolina School of Medicine

Tracks

Related Products

Thumbnail for EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Thumbnail for SMALL GROUP DISCUSSIONS IN ROOM
SMALL GROUP DISCUSSIONS IN ROOM
This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field…
Thumbnail for EOSINOPHILIC ESOPHAGITIS
EOSINOPHILIC ESOPHAGITIS
This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field…
Thumbnail for THE INDEX OF SEVERITY FOR EOSINOPHILIC ESOPHAGITIS (I-SEE) REFLECTS CLINCOPATHOLOGIC CHANGES OVER TIME IN A PEDIATRIC COHORT
THE INDEX OF SEVERITY FOR EOSINOPHILIC ESOPHAGITIS (I-SEE) REFLECTS CLINCOPATHOLOGIC CHANGES OVER TIME IN A PEDIATRIC COHORT
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…